Sustained Release Antiparkinson Agents: Controlled Release Levodopa [PDF]
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 1992 ABSTRACT:The rationale for sustained release oral levodopa preparations is to deliver levodopa in the areas of maximal intestinal absorption in a slow and predictable way, leading to stable plasma levodopa levels and brain dopamine levels, therefore resulting in a lengthened duration of action.
Serge Gauthier, Donna Amyot
openalex +3 more sources
Fistulization of J-PEG Jejunal Tube into the Colon in a Patient Treated with Duodopa® Infusion: A Case Report [PDF]
GE: Portuguese Journal of Gastroenterology, 2017 The continuous delivery of a levodopa/carbidopa gel suspension (Duodopa®) into the small bowel through a jejunal tube inserted via percutaneous endoscopic gastrostomy represents a new treatment method in advanced Parkinson disease.
Pedro Russo +6 more
doaj +4 more sources
The use of anticholinergic antiparkinson agents in Norway: Epidemiology, toxicology and clinical implications [PDF]
, 2010 This thesis is based on two fundamental questions: Which patients are currently using anticholinergic antiparkinson drugs? Does it matter which anticholinergic antiparkinson drug they are using?
Pål Gjerden
openalex +4 more sources
Anticonvulsant Activity of Antiparkinsonism Agents
Experimental Biology and Medicine, 1968 SummaryThe anticonvulsant activity of synthetic antiparkinsonism agents has been studied in mice with experimental seizures and in children with myoclonic spasms refractory to conventional medications. Procyclidine and trihexyphenidyl protected mice from maximal electroshock seizures.
J Gordon Millichap +2 more
openalex +3 more sources
Impact of insufficient drug efficacy of antiparkinson agents on patient's quality of life: a cross-sectional study. [PDF]
BMC Neurol, 2015 Tsugawa J +5 more
europepmc +3 more sources
Drug interaction (19. combination with antiparkinson agents)
Okayama Igakkai Zasshi (Journal of Okayama Medical Association), 2010 Satoru Ezumi +3 more
openalex +3 more sources
Validation of 19-items wearing-off (WOQ-19) questionnaire to Portuguese [PDF]
Arquivos de Neuro-Psiquiatria, 2020 Background: The treatment of Parkinson disease with dopaminergic therapy improves functionality and quality of life. However, as the disease progresses, the wearing-off phenomenon develops.
Carlos Eduardo MANTESE +3 more
doaj +1 more source
Arquivos de Neuro-Psiquiatria, 2022 The treatment of Parkinson's disease (PD) is challenging, especially since it is considered highly individualized. The Brazilian Academy of Neurology has recognized the need to disseminate knowledge about the management of PD treatment, adapting the best
Roberta Arb Saba +21 more
doaj +1 more source
2. Neuromuscular Disorders due to Adverse Effects of Antiparkinson Agents
Nihon Naika Gakkai Zasshi, 2007 Nobutaka Hattori
openalex +3 more sources
Treatment of Acute Neuroleptic‐Induced Movement Disorders [PDF]
, 1994 Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90365/1/j.1875-9114.1994.tb02851.x ...
Guthrie, Sally K., Tonda, Margaret E.
core +1 more source